{"id":70699,"date":"2026-05-12T09:19:23","date_gmt":"2026-05-12T09:19:23","guid":{"rendered":"https:\/\/medsbase.com\/?post_type=product&p=70699"},"modified":"2026-05-21T07:14:10","modified_gmt":"2026-05-21T07:14:10","slug":"selank","status":"publish","type":"product","link":"https:\/\/medsbase.com\/nl\/selank\/","title":{"rendered":"Selank"},"content":{"rendered":"

<\/p>\n

\n

Quick Answer \u2014 What is Selank?<\/h3>\n

Selank<\/strong> is a 7-amino-acid synthetic heptapeptide developed at the Russian Academy of Sciences as an analog of the endogenous immunomodulatory peptide tuftsin. In published research it acts as an anxiolytic nootropic, modulating GABAergic, serotonergic, and enkephalin signalling and upregulating BDNF expression without the sedation or dependence profile of benzodiazepines. Supplied in 5\u00a0mg and 10\u00a0mg lyophilized vials for laboratory research use only.<\/p>\n<\/div>\n

Wat u krijgt bij MedsBase:<\/strong> Onderzoekskwaliteit lyofiliseerde peptiden \u00b7 HPLC \u226599% zuiverheid (COA op aanvraag) \u00b7 Discrete temperatuurstabiele verpakking \u00b7 Wereldwijde peptidekoerier \u00b7 1.400+ geverifieerd klantbeoordelingen<\/a><\/div>\n

\ud83d\udce6 Elke bestelling is gedekt door onze Reshipment Assurance Policy<\/strong><\/a> \u2014 als uw pakket niet binnen 20 werkdagen arriveert, sturen wij het opnieuw.<\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n
Specificatie<\/th>\nDetail<\/th>\n<\/tr>\n<\/thead>\n
CAS-nummer<\/strong><\/td>\n129954-34-3<\/td>\n<\/tr>\n
Molecuulformule<\/strong><\/td>\nC33<\/sub>H57<\/sub>N11<\/sub>O9<\/sub><\/td>\n<\/tr>\n
Moleculair gewicht<\/strong><\/td>\n751.88 Da<\/td>\n<\/tr>\n
Sequentie<\/strong><\/td>\nThr-Lys-Pro-Arg-Pro-Gly-Pro-NH2<\/sub> (TKPRPGP-NH2<\/sub>, 7 amino acids; C-terminally amidated tuftsin analog)<\/td>\n<\/tr>\n
Form<\/strong><\/td>\nLyofiliseerd poeder (wit tot off-white)<\/td>\n<\/tr>\n
Zuiverheid<\/strong><\/td>\n\u226599% (HPLC geverifieerd, COA op aanvraag)<\/td>\n<\/tr>\n
Opslag<\/strong><\/td>\nLyofiliseerd: 2\u20138 \u00b0C (koelkast) voor werkvoorraad; \u221220 \u00b0C voor langdurige opslag van ongeopende flesjes. Gereconstitueerd: 2\u20138 \u00b0C, gebruik binnen ~30 dagen. Bescherm tegen licht. Vries de gereconstitueerde oplossing niet in en ontdooi deze niet.<\/td>\n<\/tr>\n
Oplosbaarheid<\/strong><\/td>\nBacteriostatic water (recommended) or sterile water for shorter use windows. Compatible with intranasal vehicle research formulations.<\/td>\n<\/tr>\n
Onderzoeksgebruik<\/strong><\/td>\nAlleen voor laboratoriumonderzoek. Niet voor humaan of veterinair diagnostisch of therapeutisch gebruik.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

<\/p>\n

What Is Selank?<\/h2>\n

Selank<\/strong> is a synthetic heptapeptide developed in the 1990s at the Institute of Molecular Genetics of the Russian Academy of Sciences, the same laboratory that developed Semax<\/a>. It is structurally an analog of the endogenous immunomodulatory tetrapeptide tuftsin (TKPR), extended at the C-terminus with a Pro-Gly-Pro tail that confers proteolytic stability and an amidated C-terminus. The tail extension dramatically extends plasma half-life relative to native tuftsin, which is degraded within minutes, while preserving the immunomodulatory activity of the parent peptide.<\/p>\n

Selank’s well-characterised sequence is TKPRPGP-NH2<\/sub>, molecular weight 751.88\u00a0Da, empirical formula C33<\/sub>H57<\/sub>N11<\/sub>O9<\/sub>. It is supplied as a high-purity lyophilized powder for reconstitution with bacteriostatic water. In Russia, Selank is approved as a prescription anxiolytic under the name Selank (intranasal spray); outside the post-Soviet bloc it is not approved by the FDA, EMA, MHRA, or any other major regulator. The research-grade Selank sold here is supplied uitsluitend voor laboratoriumonderzoek<\/strong> and is not approved for human or veterinary administration. For sister-peptide research, see our Semax<\/a> product page.<\/p>\n

Mechanism of Action \u2014 GABAergic, Serotonergic, and BDNF Pathways<\/h2>\n

What makes Selank distinctive among anxiolytic research compounds is its multi-pathway neuromodulatory profile<\/strong> without direct receptor binding to the GABAA<\/sub> benzodiazepine site \u2014 each contributing to the observed anxiolytic and nootropic phenotype in published research:<\/p>\n